

## Xeljanz® (tofacitinib) - New indication, new formulation

- On September 28, 2020, <u>Pfizer announced</u> the <u>FDA approval</u> of <u>Xeljanz (tofacitinib)</u>, for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older.
  - Use of Xeljanz in combination with biologic disease-modifying antirheumatic drugs (DMARDs) or with potent immunosuppressants such as <u>azathioprine</u> and <u>cyclosporine</u> is not recommended.
- Xeljanz is also approved for the treatment of adults with rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
- In addition to the new indication, the FDA also approved a new oral solution formulation for Xeljanz.
  - Tofacitinib is also available as immediate-release (Xeljanz) and extended-release (Xeljanz XR) tablets. Only Xeljanz tablets and oral solution are approved for pcJIA.
- The approval of Xeljanz for the new indication was based on a 44-week, two-part study (consisting of an 18-week, open-label, run-in phase, followed by a 26-week double-blind, placebo-controlled, randomized withdrawal phase) in 225 patients 2 years to 17 years of age with JIA. Patients received Xeljanz for 18 weeks (run-in phase) followed by randomization to either Xeljanz or placebo for 26 weeks (double-blind phase). The primary endpoint was the occurrence of disease flare at week 44 relative to the double-blind phase baseline at week 18.
  - Xeljanz treated patients experienced significantly fewer disease flares at week 44 vs. placebotreated patients (31% vs. 55%; p = 0.0007).
- Xeljanz carries a boxed warning for serious infections, mortality, malignancy, and thrombosis.
- The most common adverse reactions with Xeljanz use for pcJIA are consistent with adverse reactions reported in adult rheumatoid arthritis patients.
- The recommended oral dose of Xeljanz for the treatment of pcJIA is based on body weight

Body weight	Dosage
10 kg ≤ body weight < 20 kg	3.2 mg (3.2 mL oral solution) twice daily
20 kg ≤ body weight < 40 kg	4 mg (4 mL oral solution) twice daily
Body weight ≥40 kg	5 mg (one 5 mg tablet or 5 mL oral solution) twice daily

- Refer to the Xeljanz drug label for dosing for all its other indications.
- Pfizer plans to launch Xeljanz 1 mg/mL oral solution by the end of the first quarter 2021.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.